

Benjamin W Teh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7282823/publications.pdf>

Version: 2024-02-01

65
papers

1,500
citations

331259

21
h-index

344852

36
g-index

66
all docs

66
docs citations

66
times ranked

2220
citing authors

#	ARTICLE	IF	CITATIONS
1	Consensus guidelines for diagnosis, prophylaxis and management of <i>Pneumocystis jirovecii</i> pneumonia in patients with haematological and solid malignancies, 2014. <i>Internal Medicine Journal</i> , 2014, 44, 1350-1363.	0.5	169
2	Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance. <i>Medical Journal of Australia</i> , 2020, 212, 481-489.	0.8	107
3	Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy. <i>British Journal of Haematology</i> , 2015, 171, 100-108.	1.2	94
4	Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines. <i>Frontiers in Immunology</i> , 2020, 11, 579250.	2.2	72
5	Invasive fungal infections in patients with multiple myeloma: a multi-center study in the era of novel myeloma therapies. <i>Haematologica</i> , 2015, 100, e28-e31.	1.7	62
6	Infections in patients with chronic lymphocytic leukaemia: Mitigating risk in the era of targeted therapies. <i>Blood Reviews</i> , 2018, 32, 499-507.	2.8	57
7	Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis. <i>Blood Advances</i> , 2022, 6, 2014-2034.	2.5	57
8	Changing treatment paradigms for patients with plasma cell myeloma: Impact upon immune determinants of infection. <i>Blood Reviews</i> , 2014, 28, 75-86.	2.8	52
9	Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2016, 67, 21-37.	1.3	49
10	Azole antifungals and new targeted therapies for hematological malignancy. <i>Current Opinion in Infectious Diseases</i> , 2019, 32, 538-545.	1.3	49
11	CAR-T cell therapy and infection: a review. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 749-758.	2.0	47
12	Implementation of a whole of hospital sepsis clinical pathway in a cancer hospital: impact on sepsis management, outcomes and costs. <i>BMJ Open Quality</i> , 2018, 7, e000355.	0.4	41
13	Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2021. <i>Internal Medicine Journal</i> , 2021, 51, 67-88.	0.5	36
14	Impact of swine influenza and quarantine measures on patients and households during the H1N1/09 pandemic. <i>Scandinavian Journal of Infectious Diseases</i> , 2012, 44, 289-296.	1.5	34
15	Epidemiology of invasive fungal disease in lymphoproliferative disorders. <i>Haematologica</i> , 2015, 100, e462-e466.	1.7	30
16	Risks and burden of viral respiratory tract infections in patients with multiple myeloma in the era of immunomodulatory drugs and bortezomib: experience at an Australian Cancer Hospital. <i>Supportive Care in Cancer</i> , 2015, 23, 1901-1906.	1.0	30
17	Viral Respiratory Tract Infections in Allogeneic Hematopoietic Stem Cell Transplantation Recipients in the Era of Molecular Testing. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1490-1496.	2.0	29
18	Doxycycline vs. macrolides in combination therapy for treatment of community-acquired pneumonia. <i>Clinical Microbiology and Infection</i> , 2012, 18, E71-E73.	2.8	26

#	ARTICLE	IF	CITATIONS
19	Epidemiology of bloodstream infections in patients with myeloma receiving current era therapy. <i>European Journal of Haematology</i> , 2017, 98, 149-153.	1.1	26
20	Late-onset <i>Pneumocystis jirovecii</i> pneumonia post-fludarabine, cyclophosphamide and rituximab: implications for prophylaxis. <i>European Journal of Haematology</i> , 2013, 91, 157-163.	1.1	23
21	Disseminated <i>Scedosporium prolificans</i> infection in an "extensive metaboliser": navigating the minefield of drug interactions and pharmacogenomics. <i>Mycoses</i> , 2014, 57, 572-576.	1.8	23
22	Risks factors and outcomes of <i>Clostridium difficile</i> infection in patients with cancer: a matched case-control study. <i>Supportive Care in Cancer</i> , 2017, 25, 1923-1930.	1.0	22
23	Home-based care of low-risk febrile neutropenia in children—an implementation study in a tertiary paediatric hospital. <i>Supportive Care in Cancer</i> , 2021, 29, 1609-1617.	1.0	20
24	Prevention of viral infections in patients with multiple myeloma: the role of antiviral prophylaxis and immunization. <i>Expert Review of Anti-Infective Therapy</i> , 2015, 13, 1325-1336.	2.0	19
25	The epidemiology of <i>Clostridium difficile</i> infection in patients with cancer. <i>Expert Review of Anti-Infective Therapy</i> , 2016, 14, 1077-1085.	2.0	19
26	High rates of proven invasive fungal disease with the use of ibrutinib monotherapy for relapsed or refractory chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 1572-1575.	0.6	19
27	Safety and cost benefit of an ambulatory program for patients with low-risk neutropenic fever at an Australian centre. <i>Supportive Care in Cancer</i> , 2018, 26, 997-1003.	1.0	18
28	Epidemiology and Risks of Infections in Patients With Multiple Myeloma Managed With New Generation Therapies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 444-450.e3.	0.2	17
29	Epidemiology, treatment and outcomes of bloodstream infection due to vancomycin-resistant enterococci in cancer patients in a vanB endemic setting. <i>BMC Infectious Diseases</i> , 2020, 20, 228.	1.3	16
30	Bisppecific antibody therapy, its use and risks for infection: Bridging the knowledge gap. <i>Blood Reviews</i> , 2021, 49, 100810.	2.8	15
31	[¹⁸ F]FDG-PET-CT compared with CT for persistent or recurrent neutropenic fever in high-risk patients (PIPPIN): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Haematology</i> , 2022, 9, e573-e584.	2.2	15
32	A different kind of "allogeneic transplant" successful fecal microbiota transplant for recurrent and refractory <i>Clostridium difficile</i> infection in a patient with relapsed aggressive B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 512-514.	0.6	14
33	Sepsis following cancer surgery: the need for early recognition and standardised clinical care. <i>Expert Review of Anti-Infective Therapy</i> , 2016, 14, 425-433.	2.0	14
34	A messenger at the door: cytomegalovirus retinitis in myeloma patients with progressive disease. <i>Transplant Infectious Disease</i> , 2013, 15, E134-8.	0.7	12
35	COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement. <i>Internal Medicine Journal</i> , 2021, 51, 763-768.	0.5	12
36	<i>Pneumocystis jirovecii</i> pneumonia associated with gemcitabine chemotherapy: experience at an Australian center and recommendations for targeted prophylaxis. <i>Leukemia and Lymphoma</i> , 2015, 56, 157-162.	0.6	11

#	ARTICLE	IF	CITATIONS
37	A Randomized Trial of Two 2-Dose Influenza Vaccination Strategies for Patients Following Autologous Hematopoietic Stem Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2020, 73, e4269-e4277.	2.9	11
38	Choice and duration of antifungal prophylaxis and treatment in high-risk haematology patients. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 297-306.	1.3	11
39	Molecular diagnosis of <i>Pneumocystis jirovecii</i> in patients with malignancy: Clinical significance of quantitative polymerase chain reaction. <i>Medical Mycology</i> , 2014, 52, 427-432.	0.3	10
40	Predicting Risk of Infection in Patients with Newly Diagnosed Multiple Myeloma: Utility of Immune Profiling. <i>Frontiers in Immunology</i> , 2017, 8, 1247.	2.2	10
41	Epidemiology and risks for infection following cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. <i>Supportive Care in Cancer</i> , 2020, 28, 2745-2752.	1.0	9
42	Impact of a dedicated post-transplant vaccination service at an Australian cancer centre. <i>Bone Marrow Transplantation</i> , 2017, 52, 1681-1683.	1.3	8
43	Cost-effectiveness of home-based care of febrile neutropenia in children with cancer. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29469.	0.8	8
44	Hepatitis B serological changes following allogeneic bone marrow transplantation. <i>Transplant Infectious Disease</i> , 2013, 15, 98-103.	0.7	7
45	Antiviral prophylaxis for varicella zoster virus infections in patients with myeloma in the era of novel therapies. <i>Leukemia and Lymphoma</i> , 2016, 57, 1719-1722.	0.6	7
46	<i>Candida glabrata</i> fungaemia at an Australian cancer centre: epidemiology, risk factors and therapy. <i>Leukemia and Lymphoma</i> , 2015, 56, 3442-3444.	0.6	6
47	Cryptococcal infection in patients with haematological and solid organ malignancy in the era of targeted and immune-based therapies. <i>Clinical Microbiology and Infection</i> , 2020, 26, 519-521.	2.8	6
48	Levofloxacin prophylaxis in patients with myeloma. <i>Lancet Oncology</i> , The, 2020, 21, e67.	5.1	6
49	Ibrutinib and invasive fungal infections: the known, the unknown and the known unknowns. <i>Leukemia and Lymphoma</i> , 2020, 61, 2292-2294.	0.6	5
50	Low rates of invasive fungal disease in patients with multiple myeloma managed with new generation therapies: Results from a multicentre cohort study. <i>Mycoses</i> , 2021, 64, 30-34.	1.8	5
51	Between a rock and a hard place: COVID-19 vaccination and patients on rituximab therapy. <i>Leukemia and Lymphoma</i> , 2021, 62, 2820-2822.	0.6	5
52	Disseminated herpes simplex virus infection following epidermal growth factor tyrosine kinase inhibitor therapy for non-small cell lung carcinoma. <i>Internal Medicine Journal</i> , 2012, 42, 1269-1270.	0.5	4
53	Correspondence on "Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus under long-term treatment with hydroxychloroquine". <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e33-e33.	0.5	4
54	Miliary Tuberculosis Following Negative Latent Tuberculosis Infection Screening Prior to Tumor Necrosis Factor- α Antagonists: Implications for Management?. <i>Journal of Rheumatology</i> , 2012, 39, 1297-1298.	1.0	3

#	ARTICLE	IF	CITATIONS
55	<i>Staphylococcus aureus</i> meningitis: barriers to treatment. <i>Leukemia and Lymphoma</i> , 2012, 53, 1443-1444.	0.6	3
56	Impact of a hospital-wide sepsis pathway on improved quality of care and clinical outcomes in surgical patients at a comprehensive cancer centre. <i>European Journal of Cancer Care</i> , 2019, 28, e13018.	0.7	3
57	Successful identification of predictive profiles for infection utilising systems-level immune analysis: a pilot study in patients with relapsed and refractory multiple myeloma. <i>Clinical and Translational Immunology</i> , 2021, 10, e1235.	1.7	3
58	National cost savings from an ambulatory program for low-risk febrile neutropenia patients in Australia. <i>Australian Health Review</i> , 2019, 43, 549-555.	0.5	3
59	Guarding the sleeping giant: hepatitis B screening and management in patients with hematological malignancy. <i>Leukemia and Lymphoma</i> , 2014, 55, 2426-2427.	0.6	2
60	Hepatitis B reverse seroconversion despite entecavir prophylaxis in a myeloma patient on multiple novel agents: a case report and review of the literature. <i>Leukemia and Lymphoma</i> , 2021, 62, 1271-1274.	0.6	1
61	Latent infection screening and prevalence in cancer patients born outside of Australia: a universal versus risk-based approach?. <i>Supportive Care in Cancer</i> , 2021, 29, 6193-6200.	1.0	1
62	Vaccination Schedules. <i>Hematologic Malignancies</i> , 2021, , 77-105.	0.2	1
63	Victorian Specialist Immunisation Services (VicSIS) bolstering adult clinics for COVID-19 vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-6.	1.4	1
64	More than a feeling: new approach required for assessing immunosuppression. <i>Leukemia and Lymphoma</i> , 2014, 55, 975-976.	0.6	0
65	The long and short of antibiotic management for neutropenic fever in patients with haematological malignancy. <i>Lancet Haematology</i> , 2022, , .	2.2	0